These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2368713)

  • 41. ASHP statement on the pharmacy and therapeutics committee.
    Am J Hosp Pharm; 1986 Nov; 43(11):2841-2. PubMed ID: 3799625
    [No Abstract]   [Full Text] [Related]  

  • 42. When the pharmacy and therapeutics committee decides.
    Garrison TJ
    Hosp Pharm; 1979 Sep; 14(9):506-7. PubMed ID: 10243912
    [No Abstract]   [Full Text] [Related]  

  • 43. [14. Cooperation between the executive committee C 6 "Dyes in medicine and biology" and dye producers].
    Gerbig KD
    Acta Histochem; 1973; Suppl 13(0):321-6. PubMed ID: 4213583
    [No Abstract]   [Full Text] [Related]  

  • 44. [Drug committees are not necessary--therapeutic recommendations are issued anyway].
    Jönsson B
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2085-6: discussion 290-2. PubMed ID: 16097181
    [No Abstract]   [Full Text] [Related]  

  • 45. Communications between the P & T chairman and other medical staff committees.
    Palarea ER
    Hosp Formul; 1984 Jan; 19(1):36-8, 40. PubMed ID: 10264739
    [No Abstract]   [Full Text] [Related]  

  • 46. The P & T committee: descriptive survey of activities and time requirements.
    Butler CO; Manchester R
    Hosp Formul; 1986 Jan; 21(1):89, 92-5. PubMed ID: 10275083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Developing an effective P & T Committee, Part 2.
    Abramowitz PW; Godwin HN; Latiolais CJ; McDougal TR; Miller WA; Ravin RL
    Hosp Formul; 1985 Oct; 20(10):1071-2, 1078-81, 1086 passim. PubMed ID: 10273830
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Guidelines on the operation of the pharmacy and therapeutics committee and formulary.
    Linkewich JA; Prevoznik SJ
    Hosp Pharm; 1979 Jan; 14(1):7-10, 13, 16-9 passim. PubMed ID: 10240149
    [No Abstract]   [Full Text] [Related]  

  • 49. [Drug committees should be abolished because the reality has changed].
    Jönsson B; Arvidsson G; Levin LA; Rehnberg C
    Lakartidningen; 2005 Mar 14-20; 102(11):880-1; discussion 882-3. PubMed ID: 15835525
    [No Abstract]   [Full Text] [Related]  

  • 50. Do P&T committees have enough power? Plans and PBMs are divided about sharing drug prices with clinicians. Is it better to have an administrative committee determine the formulary?
    Cross M
    Manag Care; 2007 Apr; 16(4):39-42. PubMed ID: 17491288
    [No Abstract]   [Full Text] [Related]  

  • 51. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions.
    Hayman JN; Sbravati EC
    Am J Hosp Pharm; 1985 Jun; 42(6):1343-7. PubMed ID: 4014250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Drug committees' information leaflets are needed].
    Asberg KH
    Lakartidningen; 2009 Sep 16-22; 106(38):2384. PubMed ID: 19848349
    [No Abstract]   [Full Text] [Related]  

  • 53. Developing an effective P&T Committee, Part I.
    Abramowitz PW; Godwin HN; Latiolais CJ; McDougal TR; Miller WA; Ravin RL
    Hosp Formul; 1985 Jul; 20(7):827-8, 837, 841-3 passim. PubMed ID: 10271920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of the Pharmacy and Therapeutics Committee in materiel management.
    Moss RL; Bowman JD; Smith W
    Hosp Mater Manage Q; 1990 Feb; 11(3):61-5. PubMed ID: 10103649
    [No Abstract]   [Full Text] [Related]  

  • 55. [Lists presented by eight drug committees compared. The number of preparations varies. Similar views on the most expensive drugs].
    Bergman U; Myrhed M
    Lakartidningen; 1996 Apr; 93(15):1459-60. PubMed ID: 8667738
    [No Abstract]   [Full Text] [Related]  

  • 56. Getting ahead of the Pharmacy and Therapeutics Committee learning curve.
    Tadlock C
    Manag Care Interface; 2007 Jul; 20(7):12. PubMed ID: 17849726
    [No Abstract]   [Full Text] [Related]  

  • 57. P & T Committee roundtable discussion: Great Lakes region. Part II.
    McQuone M; Salberg DJ; Weintraub M
    Hosp Formul; 1984 Feb; 19(2):129-32, 136-8, 147-8. PubMed ID: 10264742
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Editorial: The ASHP council on clinical pharmacy and therapeutics.
    Zellmer WA
    Am J Hosp Pharm; 1974 Sep; 31(9):831. PubMed ID: 4423139
    [No Abstract]   [Full Text] [Related]  

  • 59. The future of drug product selection in health care and the role of the pharmacy and therapeutics committee.
    Cohen P
    Manag Care Interface; 2006 Dec; 19(12):15-6. PubMed ID: 17274477
    [No Abstract]   [Full Text] [Related]  

  • 60. Cost containment efforts of a pharmacy and therapeutics committee.
    Slavick HE; Simon LS
    QRB Qual Rev Bull; 1984 Feb; 10(2):38-41. PubMed ID: 6424076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.